Elisabeth Lilian Pia Sattler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Elisabeth Lilian Pia Sattler has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
- Arshed A. Quyyumi
Emory University School of Medicine
3 shared publications - Bamba Gaye
Alliance for Medical Research in Africa, Dakar, Senegal
3 shared publications - Donglan Zhang
Division of Health Services Research, Department of Foundations of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY, USA
3 shared publications - Rupal Trivedi
Department of Clinical and Administrative Pharmacy, College of Pharmacy, University of Georgia, Athens, GA, United States
3 shared publications - Sandra B. Dunbar
Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, Georgia
3 shared publications Yuta Ishikawa
3 shared publications
Latest Publications
- Open Access
- 28 July 2026
- Published by Elsevier in SSRN Electronic Journal
Global Inequalities in Cardiometabolic Care and Achievable Cardiovascular Risk Reduction by Wealth, Region, and Sex: A Pooled Analysis of Individual Participant Data From 76 Countries
Background: Wealth-related inequalities affect cardiometabolic health worldwide, but their implications for cardiometabolic care and potentially preventable cardiovascular disease remain poorly understood. Methods: We analysed harmonised, nationally representative health examination surveys from 76 countries (109 surveys) in five WHO regions. Adults aged 18 years or older with data on age, sex, wealth, and at least one cardiometabolic outcome were eligible. Disease status was defined from measured biomarkers, self-reported diagnosis, or current medication; awareness and treatment were based on self-reported information, and control on measured biomarkers. Each indicator was expressed as the proportion of all individuals with the corresponding condition. Inequality was quantified by the wealthiest–poorest quintile difference and the slope index of inequality (SII). Predicted 10-year cardiovascular risk was estimated with Globorisk, and trial-derived relative risk reductions applied to estimate achievable absolute risk reduction. Findings: Among 315 403 participants (median age 40 years [IQR 30–52]; 185 209 [58·7%] women), inequalities widened progressively across the care cascade in all regions and were most pronounced for disease control. Pooled across regions, the SII for control increased from hypertension (0·04, 95% CI 0·02–0·06) to diabetes (0·05, 0·01–0·09) and hypercholesterolaemia (0·07, 0·04–0·09). However, regional patterns varied substantially. In the Americas, disease control consistently favoured wealthier individuals (hypertension SII 0·09, 0·01–0·18), whereas in Africa coverage was uniformly low, and the largest inequality was pro-poor, particularly for hypercholesterolaemia treatment (SII −0·38, −0·50 to −0·26). Baseline cardiovascular risk was higher among the poorest (13·6% vs 12·2%), but achievable risk reduction aligned more closely with baseline risk than with treatment coverage being greatest in Europe (3·9%) and lowest in Africa (2·5%). Across all regions, achievable risk reduction was greater in men than in women (EURO 4·6% vs 3·5%), reflecting sex-specific risk functions rather than differences in access to care. Interpretation: Populations with the largest treatment gaps are not necessarily those in which expanding treatment would prevent the greatest burden of cardiovascular disease. In settings where coverage is uniformly low, expanding the supply of care matters more than redistributing access to it. Moreover, because socioeconomic inequalities widen after diagnosis, screening alone is unlikely to reduce disparities unless accompanied by sustained access to treatment. Policy should therefore define whether its primary objective is to maximise equity or overall population health gains.
- 28 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessGlobal Inequalities in Cardiometabolic Care and Achievable Cardiovascular Risk Reduction by Wealth, Region, and Sex: A Pooled Analysis of Individual Participant Data From 76 Countries
Background: Wealth-related inequalities affect cardiometabolic health worldwide, but their implications for cardiometabolic care and potentially preventable cardiovascular disease remain poorly understood. Methods: We analysed harmonised, nationally representative health examination surveys from 76 countries (109 surveys) in five WHO regions. Adults aged 18 years or older with data on age, sex, wealth, and at least one cardiometabolic outcome were eligible. Disease status was defined from measured biomarkers, self-reported diagnosis, or current medication; awareness and treatment were based on self-reported information, and control on measured biomarkers. Each indicator was expressed as the proportion of all individuals with the corresponding condition. Inequality was quantified by the wealthiest–poorest quintile difference and the slope index of inequality (SII). Predicted 10-year cardiovascular risk was estimated with Globorisk, and trial-derived relative risk reductions applied to estimate achievable absolute risk reduction. Findings: Among 315 403 participants (median age 40 years [IQR 30–52]; 185 209 [58·7%] women), inequalities widened progressively across the care cascade in all regions and were most pronounced for disease control. Pooled across regions, the SII for control increased from hypertension (0·04, 95% CI 0·02–0·06) to diabetes (0·05, 0·01–0·09) and hypercholesterolaemia (0·07, 0·04–0·09). However, regional patterns varied substantially. In the Americas, disease control consistently favoured wealthier individuals (hypertension SII 0·09, 0·01–0·18), whereas in Africa coverage was uniformly low, and the largest inequality was pro-poor, particularly for hypercholesterolaemia treatment (SII −0·38, −0·50 to −0·26). Baseline cardiovascular risk was higher among the poorest (13·6% vs 12·2%), but achievable risk reduction aligned more closely with baseline risk than with treatment coverage being greatest in Europe (3·9%) and lowest in Africa (2·5%). Across all regions, achievable risk reduction was greater in men than in women (EURO 4·6% vs 3·5%), reflecting sex-specific risk functions rather than differences in access to care. Interpretation: Populations with the largest treatment gaps are not necessarily those in which expanding treatment would prevent the greatest burden of cardiovascular disease. In settings where coverage is uniformly low, expanding the supply of care matters more than redistributing access to it. Moreover, because socioeconomic inequalities widen after diagnosis, screening alone is unlikely to reduce disparities unless accompanied by sustained access to treatment. Policy should therefore define whether its primary objective is to maximise equity or overall population health gains.
- Open Access
- 10 November 2025
- Published by Springer Nature in Current Epidemiology Reports
- Vol. 12 (1) , 1-9
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Post ST-Segment Elevation Myocardial Infarction Care: A Scoping Review
Purpose of review: This scoping review synthesizes current evidence on glucagon-like peptide-1 receptor agonist (GLP-1RA) use after ST-elevation myocardial infarction (STEMI), highlighting their potential as adjunctive therapy. Recent findings: Ten studies investigated exenatide and liraglutide in adults with STEMI, evaluating imaging, clinical, mechanistic, and safety outcomes. GLP-1RA use was safe and well tolerated. Exenatide demonstrated improvements in infarct size, myocardial salvage, and cardiac function, although two trials in broader STEMI populations reported no post-infarction improvements. Across three trials, liraglutide was associated with improved myocardial salvage, infarct size, left ventricular ejection fraction, stroke volume and no-reflow, supported by favorable biomarker changes, but without significant reductions in major cardiovascular events. Summary: While most existing evidence is based on studies with limited generalizability, GLP-1RA use shows promise in improving post-STEMI outcomes. The consistent benefits reported support the need for larger, multicenter trials to clarify GLP-1RA role in cardioprotection and long-term outcomes.
- 10 November 2025
- Published by Springer Nature in Current Epidemiology Reports
- Vol. 12 (1) , 1-9
Open AccessThe Role of Glucagon-Like Peptide-1 Receptor Agonists in Post ST-Segment Elevation Myocardial Infarction Care: A Scoping Review
Purpose of review: This scoping review synthesizes current evidence on glucagon-like peptide-1 receptor agonist (GLP-1RA) use after ST-elevation myocardial infarction (STEMI), highlighting their potential as adjunctive therapy. Recent findings: Ten studies investigated exenatide and liraglutide in adults with STEMI, evaluating imaging, clinical, mechanistic, and safety outcomes. GLP-1RA use was safe and well tolerated. Exenatide demonstrated improvements in infarct size, myocardial salvage, and cardiac function, although two trials in broader STEMI populations reported no post-infarction improvements. Across three trials, liraglutide was associated with improved myocardial salvage, infarct size, left ventricular ejection fraction, stroke volume and no-reflow, supported by favorable biomarker changes, but without significant reductions in major cardiovascular events. Summary: While most existing evidence is based on studies with limited generalizability, GLP-1RA use shows promise in improving post-STEMI outcomes. The consistent benefits reported support the need for larger, multicenter trials to clarify GLP-1RA role in cardioprotection and long-term outcomes.
- Open Access
- 16 February 2024
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 26, e49178
Effectiveness and Feasibility of Telehealth-Based Dietary Interventions Targeting Cardiovascular Disease Risk Factors: Systematic Review and Meta-Analysis
Background: Telehealth-based dietary interventions were recommended for cardiovascular disease (CVD) management during the COVID-19 pandemic; however, data regarding their effectiveness and feasibility are limited. Objective: We aimed to examine (1) the effectiveness of telehealth-based dietary interventions in improving clinical CVD risk factors and (2) the feasibility of these interventions among individuals with CVD. Methods: To conduct this systematic review and meta-analysis of randomized controlled trials (RCTs), 2 investigators searched PubMed, Cochrane Library, Web of Science, and ClinicalTrials.gov databases based on predetermined search terms and included English-language RCTs published between January 2000 and July 2022. The Cochrane Risk of Bias tool was used to assess RCT quality. To evaluate intervention effectiveness, weight, BMI, systolic and diastolic blood pressure, and levels of total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, or blood glucose were compared postintervention in telehealth and usual care (UC) groups. Feasibility was determined through the number of participants retained in intervention and UC groups. Pooled data for each CVD outcome were analyzed using a random effects model. Mean difference (MD), standardized MD, or risk ratio were calculated using R software. Results: A total of 13 RCTs with 3013 participants were included in the analysis to assess the effectiveness and feasibility of telehealth-based dietary interventions among individuals with CVD. Participants had a mean age of 61.0 (SD 3.7) years, and 18.5% (n=559) were women. Approximately one-third of RCTs were conducted in the United States (n=4, 31%). Included studies used telephone, app, text, audio-visual media, or website-based interventions. Of the 13 included studies, 3 were of high quality, 9 were of moderate quality, and only 1 was of low quality. Pooled estimates showed systolic blood pressure (MD –2.74, 95% CI –4.93 to –0.56) and low-density lipoprotein cholesterol (standardized MD –0.11, 95% CI –0.19 to –0.03) to be significantly improved among individuals with CVD as a result of telehealth-based dietary interventions compared to UC. No significant difference in effectiveness was detected for weight, BMI, and levels of diastolic blood pressure, total cholesterol, high-density lipoprotein, and triglycerides between telehealth-based dietary interventions and UC among those with CVD. There was no significant difference between the feasibility of telehealth-based dietary interventions versus UC. Significant I2 indicated moderate to considerable heterogeneity. Conclusions: Telehealth-based dietary interventions show promise in addressing CVD risk factors.
- 16 February 2024
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 26, e49178
Open AccessEffectiveness and Feasibility of Telehealth-Based Dietary Interventions Targeting Cardiovascular Disease Risk Factors: Systematic Review and Meta-Analysis
Background: Telehealth-based dietary interventions were recommended for cardiovascular disease (CVD) management during the COVID-19 pandemic; however, data regarding their effectiveness and feasibility are limited. Objective: We aimed to examine (1) the effectiveness of telehealth-based dietary interventions in improving clinical CVD risk factors and (2) the feasibility of these interventions among individuals with CVD. Methods: To conduct this systematic review and meta-analysis of randomized controlled trials (RCTs), 2 investigators searched PubMed, Cochrane Library, Web of Science, and ClinicalTrials.gov databases based on predetermined search terms and included English-language RCTs published between January 2000 and July 2022. The Cochrane Risk of Bias tool was used to assess RCT quality. To evaluate intervention effectiveness, weight, BMI, systolic and diastolic blood pressure, and levels of total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, or blood glucose were compared postintervention in telehealth and usual care (UC) groups. Feasibility was determined through the number of participants retained in intervention and UC groups. Pooled data for each CVD outcome were analyzed using a random effects model. Mean difference (MD), standardized MD, or risk ratio were calculated using R software. Results: A total of 13 RCTs with 3013 participants were included in the analysis to assess the effectiveness and feasibility of telehealth-based dietary interventions among individuals with CVD. Participants had a mean age of 61.0 (SD 3.7) years, and 18.5% (n=559) were women. Approximately one-third of RCTs were conducted in the United States (n=4, 31%). Included studies used telephone, app, text, audio-visual media, or website-based interventions. Of the 13 included studies, 3 were of high quality, 9 were of moderate quality, and only 1 was of low quality. Pooled estimates showed systolic blood pressure (MD –2.74, 95% CI –4.93 to –0.56) and low-density lipoprotein cholesterol (standardized MD –0.11, 95% CI –0.19 to –0.03) to be significantly improved among individuals with CVD as a result of telehealth-based dietary interventions compared to UC. No significant difference in effectiveness was detected for weight, BMI, and levels of diastolic blood pressure, total cholesterol, high-density lipoprotein, and triglycerides between telehealth-based dietary interventions and UC among those with CVD. There was no significant difference between the feasibility of telehealth-based dietary interventions versus UC. Significant I2 indicated moderate to considerable heterogeneity. Conclusions: Telehealth-based dietary interventions show promise in addressing CVD risk factors.
- Open Access
- 17 October 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (20) , e029894
Highlights From the American Heart Association's EPI|Lifestyle Scientific Sessions 2023
- 17 October 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (20) , e029894
Open AccessHighlights From the American Heart Association's EPI|Lifestyle Scientific Sessions 2023
- Open Access
- 1 June 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Effectiveness and Feasibility of Telehealth-Based Dietary Interventions Targeting Cardiovascular Disease Risk Factors: Systematic Review and Meta-Analysis (Preprint)
BACKGROUND Telehealth-based dietary interventions were recommended for cardiovascular disease (CVD) management during the COVID-19 pandemic; however, data regarding their effectiveness and feasibility are limited. OBJECTIVE We aimed to examine (1) the effectiveness of telehealth-based dietary interventions in improving clinical CVD risk factors and (2) the feasibility of these interventions among individuals with CVD. METHODS To conduct this systematic review and meta-analysis of randomized controlled trials (RCTs), 2 investigators searched PubMed, Cochrane Library, Web of Science, and ClinicalTrials.gov databases based on predetermined search terms and included English-language RCTs published between January 2000 and July 2022. The Cochrane Risk of Bias tool was used to assess RCT quality. To evaluate intervention effectiveness, weight, BMI, systolic and diastolic blood pressure, and levels of total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, or blood glucose were compared postintervention in telehealth and usual care (UC) groups. Feasibility was determined through the number of participants retained in intervention and UC groups. Pooled data for each CVD outcome were analyzed using a random effects model. Mean difference (MD), standardized MD, or risk ratio were calculated using R software. RESULTS A total of 13 RCTs with 3013 participants were included in the analysis to assess the effectiveness and feasibility of telehealth-based dietary interventions among individuals with CVD. Participants had a mean age of 61.0 (SD 3.7) years, and 18.5% (n=559) were women. Approximately one-third of RCTs were conducted in the United States (n=4, 31%). Included studies used telephone, app, text, audio-visual media, or website-based interventions. Of the 13 included studies, 3 were of high quality, 9 were of moderate quality, and only 1 was of low quality. Pooled estimates showed systolic blood pressure (MD –2.74, 95% CI –4.93 to –0.56) and low-density lipoprotein cholesterol (standardized MD –0.11, 95% CI –0.19 to –0.03) to be significantly improved among individuals with CVD as a result of telehealth-based dietary interventions compared to UC. No significant difference in effectiveness was detected for weight, BMI, and levels of diastolic blood pressure, total cholesterol, high-density lipoprotein, and triglycerides between telehealth-based dietary interventions and UC among those with CVD. There was no significant difference between the feasibility of telehealth-based dietary interventions versus UC. Significant I2 indicated moderate to considerable heterogeneity. CONCLUSIONS Telehealth-based dietary interventions show promise in addressing CVD risk factors.
- 1 June 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessEffectiveness and Feasibility of Telehealth-Based Dietary Interventions Targeting Cardiovascular Disease Risk Factors: Systematic Review and Meta-Analysis (Preprint)
BACKGROUND Telehealth-based dietary interventions were recommended for cardiovascular disease (CVD) management during the COVID-19 pandemic; however, data regarding their effectiveness and feasibility are limited. OBJECTIVE We aimed to examine (1) the effectiveness of telehealth-based dietary interventions in improving clinical CVD risk factors and (2) the feasibility of these interventions among individuals with CVD. METHODS To conduct this systematic review and meta-analysis of randomized controlled trials (RCTs), 2 investigators searched PubMed, Cochrane Library, Web of Science, and ClinicalTrials.gov databases based on predetermined search terms and included English-language RCTs published between January 2000 and July 2022. The Cochrane Risk of Bias tool was used to assess RCT quality. To evaluate intervention effectiveness, weight, BMI, systolic and diastolic blood pressure, and levels of total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, or blood glucose were compared postintervention in telehealth and usual care (UC) groups. Feasibility was determined through the number of participants retained in intervention and UC groups. Pooled data for each CVD outcome were analyzed using a random effects model. Mean difference (MD), standardized MD, or risk ratio were calculated using R software. RESULTS A total of 13 RCTs with 3013 participants were included in the analysis to assess the effectiveness and feasibility of telehealth-based dietary interventions among individuals with CVD. Participants had a mean age of 61.0 (SD 3.7) years, and 18.5% (n=559) were women. Approximately one-third of RCTs were conducted in the United States (n=4, 31%). Included studies used telephone, app, text, audio-visual media, or website-based interventions. Of the 13 included studies, 3 were of high quality, 9 were of moderate quality, and only 1 was of low quality. Pooled estimates showed systolic blood pressure (MD –2.74, 95% CI –4.93 to –0.56) and low-density lipoprotein cholesterol (standardized MD –0.11, 95% CI –0.19 to –0.03) to be significantly improved among individuals with CVD as a result of telehealth-based dietary interventions compared to UC. No significant difference in effectiveness was detected for weight, BMI, and levels of diastolic blood pressure, total cholesterol, high-density lipoprotein, and triglycerides between telehealth-based dietary interventions and UC among those with CVD. There was no significant difference between the feasibility of telehealth-based dietary interventions versus UC. Significant I2 indicated moderate to considerable heterogeneity. CONCLUSIONS Telehealth-based dietary interventions show promise in addressing CVD risk factors.
- Open Access
- 18 April 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (8)
American Heart Association EPI|Lifestyle Scientific Sessions: 2022 Meeting Highlights
- 18 April 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (8)
Open AccessAmerican Heart Association EPI|Lifestyle Scientific Sessions: 2022 Meeting Highlights
- Open Access
- 6 April 2023
- Published by BMJ in Open Heart
- Vol. 10 (1) , e002222
Association of Life’s Simple 7 and ideal cardiovascular health in American Indians/Alaska Natives
Objective American Indians and Alaska Natives (AI/ANs) are an understudied population at high risk for cardiovascular diseases (CVDs); little is known about contextual factors contributing to CVDs in AI/ANs. This study examined the association of Life’s Simple 7 (LS7) factors and social determinants of health (SDH) with CVD outcomes in a nationally representative sample of AI/ANs. Methods We conducted a cross-sectional study of 8497 AI/ANs using 2017 Behavioural Risk Factor Surveillance Survey data. Individual LS7 factors were summarised as ideal and poor levels. Coronary heart disease, myocardial infarction and stroke were defined as CVD outcomes. Healthcare access measures represented SDH. Logistic regression analyses examined associations of LS7 factors and SDH with CVD outcomes. Population attributable fractions (PAFs) quantified individual contributions of LS7 factors to CVD outcomes. Results N=1,297 (15%) participants with CVD outcomes were identified. Smoking, physical inactivity, diabetes, hypertension and hyperlipidaemia were LS7 factors associated with CVD outcomes. Hypertension was the largest contributor to CVD (aPAF 42%; 95% CI 37% to 51%), followed by hyperlipidaemia (aPAF 27%; 95% CI 17% to 36%) and diabetes (aPAF 18%; 95% CI 7% to 23%). Compared with individuals with poor LS7 levels, participants with ideal levels showed 80% lower odds of CVD outcomes (aOR 0.20; 95% CI 0.16 to 0.25). Access to health insurance (aOR 1.43, 95% CI 1.08 to 1.89) and a regular care provider (aOR 1.47, 95% CI 1.24 to 1.76) were associated with CVD outcomes. Conclusions Effective interventions are needed to address SDH and attain ideal LS7 factors to improve cardiovascular health among AI/ANs.
- 6 April 2023
- Published by BMJ in Open Heart
- Vol. 10 (1) , e002222
Open AccessAssociation of Life’s Simple 7 and ideal cardiovascular health in American Indians/Alaska Natives
Objective American Indians and Alaska Natives (AI/ANs) are an understudied population at high risk for cardiovascular diseases (CVDs); little is known about contextual factors contributing to CVDs in AI/ANs. This study examined the association of Life’s Simple 7 (LS7) factors and social determinants of health (SDH) with CVD outcomes in a nationally representative sample of AI/ANs. Methods We conducted a cross-sectional study of 8497 AI/ANs using 2017 Behavioural Risk Factor Surveillance Survey data. Individual LS7 factors were summarised as ideal and poor levels. Coronary heart disease, myocardial infarction and stroke were defined as CVD outcomes. Healthcare access measures represented SDH. Logistic regression analyses examined associations of LS7 factors and SDH with CVD outcomes. Population attributable fractions (PAFs) quantified individual contributions of LS7 factors to CVD outcomes. Results N=1,297 (15%) participants with CVD outcomes were identified. Smoking, physical inactivity, diabetes, hypertension and hyperlipidaemia were LS7 factors associated with CVD outcomes. Hypertension was the largest contributor to CVD (aPAF 42%; 95% CI 37% to 51%), followed by hyperlipidaemia (aPAF 27%; 95% CI 17% to 36%) and diabetes (aPAF 18%; 95% CI 7% to 23%). Compared with individuals with poor LS7 levels, participants with ideal levels showed 80% lower odds of CVD outcomes (aOR 0.20; 95% CI 0.16 to 0.25). Access to health insurance (aOR 1.43, 95% CI 1.08 to 1.89) and a regular care provider (aOR 1.47, 95% CI 1.24 to 1.76) were associated with CVD outcomes. Conclusions Effective interventions are needed to address SDH and attain ideal LS7 factors to improve cardiovascular health among AI/ANs.
- Open Access
- 1 September 2022
- Published by Elsevier in Diabetes Epidemiology and Management
- Vol. 9
Comparison of diagnostic screening methods for diabetes in patients with heart failure
- 1 September 2022
- Published by Elsevier in Diabetes Epidemiology and Management
- Vol. 9
Open AccessComparison of diagnostic screening methods for diabetes in patients with heart failure
- 15 January 2022
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 184, 109191
Prevalence and trends of type 2 diabetes mellitus and prediabetes among community-dwelling heart failure patients in the United States
- 15 January 2022
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 184, 109191
Prevalence and trends of type 2 diabetes mellitus and prediabetes among community-dwelling heart failure patients in the United States